The insulin resistance syndrome: Concept and therapeutic approaches

Pharmacotherapy of Diabetes: New Developments: Improving Life and Prognosis for Diabetic Patients

Volumn , Issue , 2007, Pages 19-30

  Reaven, Gerald M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hyperinsulinemia; insulin resistance; Insulin resistance syndrome; obesity; weight loss

Indexed keywords

EID: 77954906883     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69737-6_3     Document Type: Chapter

References (79)

1. Himsworth HP. The mechanism of diabetes mellitus. I. Lancet 1939;II:1-6.
2. Himsworth HP. The mechanism of diabetes mellitus. II. The control of blood sugar level. Lancet 1939;II: 65-68.
3. Himsworth HP The mechanism of diabetes mellitus. II. The control of blood sugar level (cont). Lancet 1939;II:118-132.
4. Himsworth HP. The mechanism of diabetes. III. Human diabetes mellitus. Lancet 1939;II:171-175.
5. Himsworth HP. The syndrome of diabetes and its causes. Lancet 1949;2:465-473.
6. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39:1157-1175.
7. Shen S-W, Reaven GM, Farquhar JW. Comparison of impedance to insulin mediated glucose uptake in normal and diabetic subjects. J Clin Invest 1970; 49:21518.
8. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
9. Ginsberg H, Olefsky JM, Reaven GM. Further evidence that insulin resistance exists in patients with chemical diabetes. Diabetes 1974;23:674-678.
10. Ginsberg H, Kimmerling G, Olefsky JM, et al. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest 1975;55:454-461.
11. Reaven GM. Insulin resistance in noninsulindependent diabetes mellitus. Does it exist and can it be measured? Am J Med 1983;74 (Suppl. 1A):3-17.
12. Warram JH, Martin BC, Krowlewski As, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the off-spring of the diabetic parents. Ann Intern Med 1990;113: 909-915.
13. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus N Engl J Med 1993;329:1988-1992.
14. Hollenbeck CB, Reaven GM. Variations in insulinstimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 1987;64:1169-1173.
15. Yeni-Komshian H, Carantoni M, Abbasi F, et al. Relationship between several surrogate estimates of insulin resistance and quantification of insulinmediated glucose disposal in 490 healthy, nondiabetic volunteers. Diabetes Care 2000;23:171-175.
16. Reaven GM, Hollenbeck CB, Chen Y-DI. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 1989;32:52-55.
17. Reaven GM, Lerner RL, Stern MP, et al Role of insulin in endogenous hypertriglyceridemia. J Clin Invest 1967;46:1756-1767.
18. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974;57:551-560.
19. Tobey TA, Greenfield M, Kraemer F, et al. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man. Metabolism 1981;30:165-171.
20. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insul in concentrations. J Int Med 1992;231:25-30.
21. Ferrannini E, Buzzigoli G, Bonadona R. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-357
22. Shen D-C, Shieh S-M, Fuh M, et al.Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988;66:580-583.
23. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275: 1571-1576.
24. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2385-2387.
25. Austin MA, Hokanson JE, Edwards KI. Hypertriglycridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(4A):7B-12B.
26. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
27. Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep 2003;5:364-371.
28. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement: the insulin resistance syndrome. Endocrine Practice 2003;9:237-252.
29. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
30. Executive Summary of Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
31. Alberti KGMM, Zimmet P, Shaw J and for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet 2005;366:1059-1062.
32. Reaven GM. The metabolic syndrome: Requiescat in pace. Clin Chem 2005;51:931-938.
33. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304.
34. Gale EA. The myth of the metabolic syndrome. Diabetologia 2005;48:1679-1683.
35. Reaven GM. The metabolic syndrome: is this diagnosis necessary. Am J Clin Nutr 2006;83:1237-1247.
36. Abbasi F, McLaughlin T, Lamendola C, et al. The relationship between glucose disposal in response to physiological hyperinsulinemia and basal glucose and free fatty acid concentrations in healthy volunteers. J Clin Endocrinol Metab 2000;85:1251-1254.
37. Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Diseases. 1997;30: 928-931.
38. Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin. J Clin Endocrinol Metab 2006;91; 22-24.
39. Olefsky JM. Reaven GM, Farquhar JW. Effects of weight reduction on obesity: studies of carbohydrate and lipid metabolism. J Clin Invest 1974;53:64-76.
40. Su H-Y, Sheu WH-H, Chin H-ML, et al. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am J Hypertens 1995;8:1067-1071.
41. Moran LJ, Noakes M, Clifton PM, et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88: 812-819.
42. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease. Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-1654.
43. Tuomilehto J, Lindstrom J, Eriksson JG, et al. 2001. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350.
44. Knowler WC, Barrett-Connor E, Fowler SE, et al for The Diabetes Prevention Program Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346: 393-403.
45. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998;83:2773-2776.
46. Facchini, FS, Hua, N, Abbasi, F, et al. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001;86:3574-3578.
47. McLaughlin T, Allison G, Abbasi F, et al. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004;53:495-499.
48. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-809.
49. Kim SH, Abbasi F, Reaven G. Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 2004;27:1998-2002.
50. Valdez R, Mitchell BD, Haffner SM, et al. Predictors of weight change in a bi-ethnic population. The San Antonio Heart Study. Int J Obes 1984;18:85-91.
51. Swinburn BA, Nyomba BL, Saad MF, et al. Insulin resistance associated with lower rates of weight gain in Pima Indians. J Clin Invest 1991;88: 168-173.
52. Hoag S, Marshall JA, Jones RH, et al. High fasting insulin levels associated with lower rates of weight gain in persons with normal glucose tolerance: The San Luis Valley Diabetes Study. Int J Obes 1995;19: 175-180.
53. Schwartz MW, Boyko EJ, Kahn SE, et al. Reduced insulin secretion: An independent predictor of body weight gain. J Clin Endocrinol Metab 1995;80: 1571-1576.
54. Zavaroni I, Zuccarelli A, Gasparini P, et al. Can weight gain in healthy, nonobese volunteers be predicted by differences in baseline plasma insulin concentrations? J Clin Endocrinol Metab. 1998;83: 3498-3500.
55. McLaughlin T, Abbasi F, Carantoni M, et al. Differences in insulin resistance do not predict weight loss in response to hypocaloric diets in healthy obese women. J Clin Endocrinol Metab 1999;84:578-581.
56. McLaughlin T, Abbasi F, Lamendola C, et al. Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. Metabolism 2001;50:819-882.
57. McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002;106:2908-2912.
58. McLaughlin T, Stuhlinger M, Lamendola C, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin resistant women and fall with weight loss. J Clin Endocrinol Metab 2006;91: 1896-2000.
59. Wu M-S, Johnston P, Sheu W H-H, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990;13:1-8.
60. Hollenbeck CB, Johnston P, Varasteh, BB, et al. Effects of metformin on glucose insulin and lipid metabolism in patients with mild hypertryglyceridaemia and noninsulin dependent diabetes by glucose tolerance test criteria. Diabete Metab 1991;17:483-489.
61. Reaven GM. Effect of metformin on various aspects of glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus with varying degrees of hyperglycemia. Diab/Metab Rev 1995;11:S97-S108.
62. Chu JW Abbasi F Lamendola C, et al. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes Vasc Dis Res 2005;2:37-41.
63. Kim SH, Abbasi F, Chu, et al. Rosiglitazone reduces glucose-stimulated insulin secretion and increases insulin clearance in nondiabetic, insulin resistant individuals. Diabetes 2005;54:2447-2452
64. Abbasi F, Chang S-A, Chu JW, GM, Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, is not correlated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Integr Comp Physiol 2006;290: R 139-144, 47.
65. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-196.
66. Cataldo NA, Abbasi F, Mclaughlin TL, et al. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Repro 2006;1: 109-120.
67. The Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 2003;26:977-980.
68. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368: 1096-1105.
69. Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin N Am. 2005;34:49-62.
70. Austin MA, Breslow JL, Hennekens CH, et al. Lowdensity lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-1921.
71. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 1992;12:1336-1345.
72. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.
73. Robins SJ, Collins D, Wittes, JT, et al. Relation of gemfibrozil and lipid levels with major coronary events: VA-HIT: a randomized control trial. JAMA 2001;285:1585-1591.
74. Robins SJ, Rubins HB, Fass FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513-1517.
75. Zavaroni I, Mazza S, Dall'Aglio E, et al. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992; 231:235-240.
76. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003;88: 2399-2403.
77. Sheuh WH-H, Jeng C-Y, Shieh S-M, et al. Insulin resistance and abnormal electrocardiograms in patients with high blood pressure. Am J Hypertens 1992;5:444-448.
78. Jeppesen J, Hein HO, Suadicani P, et al. High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease. Hypertension 2000;36:226-239.
79. Jeppesen J, Hein HO, Suadicani P, et al. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Int Med 2001;161:361-366.